Exceptions for inventions involving the treatment of humans (including CAR T)
Author: James Love
KEI Comments on Negotiating Objectives for a U.S.-U.K. Trade Agreement
KEI Comments Regarding the NIST Special Publication 1234 Draft Green Paper on Return on Public Investment
KEI filed comments on the NIST Draft Green paper on the return from investment on federally funded R&D (See: https://www.keionline.org/29518). We expect the comment period to be extended, but filed this on January 9, 2018, as an initial submission. KEI-comments-NIST-SP-1234-ROI-9Jan2018… Continue Reading
KEI Comments on Medicare Programs: International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM)
KEI Comments on Medicare Programs: International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Knowledge Ecology International (KEI) is a non-profit organization that focuses on the management of knowledge goods, including new drugs, vaccines and other medical therapies. Much… Continue Reading
The December 2018 NIST Draft Green paper on “Return on Investment”
In December 2018, the Department of Commerce National Institute of Standards (NIST) published NIST Special Publication 1234, “Return on Investment Initiative for Unleashing American Innovation” as a draft Green Paper. According to the initial release, before the government shutdown, comments… Continue Reading
2018: KEI comments on Navy proposed exclusive license to Vedevo for data compression patent
Office of Research and Technology Applications, Naval Postgraduate School, Research and Sponsored Programs Office, NPS Code 41, 699 Dyer Road, Bldg. HA, Room 226, Via. Ms. Deborah Buettner, Director, Research and Sponsored Programs Office, email: dbuettne@nps.edu Dear Deborah Beuttner, We… Continue Reading
2018: Comments on NIH license to Bull Run Capital, Inc. for safer non-lethal antagonist
Jaime M. Greene Senior Licensing and Patenting Manager NCI Technology Transfer Center Email: greenejaime@mail.nih.gov December 16, 2018 Re: Comments on “Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use for certain inventions” (83 FR 61659) Dear… Continue Reading
Pfizer asked USTR to block Malaysia requirement on drug price transparency. September 2017
KEI has received Pfizer and USTR emails and a Pfizer briefing memo to USTR from September 2017, asking the USTR to block a Malaysia Requirement to disclose drug prices. The documents were obtained under a Freedom of Information request to… Continue Reading
Communications between Gilead and USTR regarding Malaysia compulsory license on HCV patents, 2017 to May 2018
The attached document is a 78 page PDF file obtained from USTR under the Freedom of Information Act (copy here), regarding communications between Gilead and USTR, over Malaysia’s decision to grant a compulsory license on patents for HCV treatments. This… Continue Reading
US delegation circulates a new paper on the WIPO Broadcast treaty
This will be discussed next week at the SCCR 37 Standing Committee on Copyright and Related Rights (SCCR) Thirty-Seventh Session Geneva, November 26- 30, 2018 PROPOSAL OF THE UNITED STATES OF AMERICA ON THE SCOPE AND IMPLEMENTATION OF RIGHTS, WIPO… Continue Reading